Evaluating the Implementation of a Need-Based Cancer Survivorship Program

Reach will be assessed as the percentage of eligible patients being assessed, advised, and referred based on need. Clinical units will submit weekly records of eligible patients assessed, advised, and referred to JCICC/NGO/DHC partners. The investigators will measure referral uptake through the proportion of patients accepting moderate- and high-need programs, examining attendance patterns and attrition rates. Weekly records will be collected from JCICC and NGO/DHC partners.

Adoption refers to the proportion of intervention agents willing to initiate the program, including patient volunteers, HCPs from clinical units, and NGO partner staff. For patient volunteers, the investigators assessed enrollment and training completion rates, requiring minimum 50% enrollment by potential active members. For HCPs and NGO/DHC staff, the investigators will calculate participation rates. The acceptability, appropriateness, and feasibility will be measured using the four-item Acceptability of Intervention Measure (AIM), the Intervention Appropriateness Measure (IAM) and Feasibility of Intervention Measure (FIM). Each item is rated on a 5-point Likert scale ranging from 1 to 5 to measure the agreeability, with higher scores indicating greater acceptability, appropriateness, and feasibility.

Effectiveness of need-based cancer survivorship program will be assessed on patients' outcomes including symptom distress, weight control, health-related quality of life, work productivity and activity impairment, lifestyle changes (such as physical activity levels, diet quality, alcohol consumption, and smoking habits), knowledge and awareness of symptom management and overall health condition, satisfaction with services received, and health care utilization.

The Edmonton Symptom Assessment System (ESAS) will be used to assess symptom distress. The ESAS assesses 13 common symptoms, including pain, fatigue, sleep difficulties, numbness, worrying, feeling sad, or feeling nervous, using a 10-point Likert scale. Patients rating at least one symptom at =>7 will be categorized as moderate-to-severe symptom distress cases.

The investigators will use the weight machine in the clinic to measure weight in kilograms and height in centimeters. Weight and height will be used to calculate BMI in kg/m². Based on Asia-Pacific cutoffs, individuals with a normal BMI (18.5-22.9) or overweight BMI (23.0-24.9) will be classified accordingly. Individuals with an obese BMI (>25.0) will be classified as having preclinical-to-clinical obesity.

The EORTC QLQ-C30 includes 30 items that measure five function scales (physical, role, emotional, cognitive, and social), three symptom scales (fatigue, pain, and nausea/vomiting), a global health QoL subscale, five single symptom items (dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea) and financial difficulty.

The generic EQ-5D-5L questionnaire evaluates five dimensions including mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. Each dimension is rated on a 5-level scale (1 = no problem; 2 = slight problem; 3 = moderate problem; 4 = severe problem; 5 = extreme problem). A continuous response scale ranging from 0 (worst possible health state) to 100 (best possible health state), to assess their self-rated health on the assessment day.

The 6-item WPAI measures work productivity loss (the extent to which current health condition induced work inability) and activity impairment (the extent to which current health condition affected regular activities other than job-related work). Items assessing work productivity loss are only relevant to those who have returned to work. Both work productivity loss and activity impairment are expressed in percentages, with higher values indicative of greater productivity loss and impaired functioning

Physical activity level will be assessed using the Global Physical Activity Questionnaire (GPAQ) developed by WHO. The GPAQ consists of 16 items designed to assess participants' physical activity level in work, transport and leisure time, and assess time spent in sedentary behaviours. Satisfactory convergent validly of the measure of moderate-to-vigorous physical activity was reported.

The Patient Activation Measure (PAM-13) will be used to measure the patient's knowledge, skills and confidence. PAM-13 is a validated, non-disease-specific instrument applicable across diverse populations and healthcare settings, including cancer survivorship. It consists of 13 items rated on a 4-point Likert scale (1 = strongly disagree to 4 = strongly agree), yielding a raw score between 13 and 52. This raw score is then transformed into a standardized activation score ranging from 0 to 100, with higher scores indicating greater patient activation.

Self-efficacy will be assessed by Self-Efficacy for Managing Chronic Disease scale (SEMCDS).This is a 6-item scale assessing patients' confidence to perform six self-management behaviours. Each item is rated on a 10-point Likert scale. A high score indicates high self-efficacy.